Description

This course is an introduction to Antimicrobials in Veterinary Medicine. It will provide background, context and understanding regarding Absorption, Distribution, Metabolism and Excretion (ADME) of this class of compounds, along with spectrum of activity, typical indications for each class, and relevant target animal and human food safety. In addition, there will be a limited discussion regarding potential clinical use and unmet needs in each class. For each class, some discuss will be done regarding PK/PD relationship and S, I, & R testing and interpretation. This seminar will provide attendees with a basic understanding of Veterinary Antimicrobials in the context of veterinary drug development.

Learning Objectives:

Upon completing this course on veterinary antimicrobials participants will have learned:

• To be able to describe the basic mechanisms of action (MOA) of each antimicrobial class of agents.
• Relate the states below to the dosage regimen and expected results of therapy:
  • Immune and cellular defense systems
  • Renal function
  • Hepatic function
  • Stage of infection
• To be able to discuss the different types of undesirable responses exhibited by antimicrobial agents to veterinarians, scientist, regulators, and peers.

Who will Benefit:

This course is designed for people tasked with developing and maintaining an animal health company's product portfolio and involved with a company's regulatory strategies. This includes individuals responsible for regulatory affairs, developing veterinary drug products, evaluating new technologies or applications, and those tasked with ensuring corporate compliance. Among others, this includes:

• Personnel new to the Animal Health Industry
• Scientists in Veterinary Drug Development
• Entrepreneurs and small business owners wanting to understanding antimicrobials
• CRO professionals
• Entrepreneurs looking to add value to their products
• Regulatory professionals
• Process owners
• Financial Advisors and Institutional Investors
• Consultants, Inspectors and cGxP Experts

Rob Hunter
Veterinary Drug Development Specialist

Seminar Instructor Rob Hunter has 20 years of veterinary and human drug development experience with NASA, Pfizer, Elanco, Parnell, and Provetica. He has contributed to the approvals for Revolution®, Dectomax®, Ovugel®, and Pulmotil®, with others currently in development or under regulatory review. Internationally recognized subject matter expert on pharmacokinetics, antimicrobial PK/PD, interspecies allometry, drug metabolism, bioequivalence, and tissue residues/human food safety along with corresponding bioanalytical support. Dr. Hunter has served on and chaired several AHI committees and represented the U.S. veterinary pharmaceutical industry on the VICH bioequivalence expert committee. He has represented various companies at CVM/FDA, EMA/CVMP, APVMA, VDD (Canada), NVQRS/QIA (South Korea), Thailand FDA, NVAL (Japan), Ministry of Agriculture (Vietnam), and IVDC (China) regarding specific products, issues, and/or policies.

Please contact the event manager Marilyn below for the following: 
- Discounts for registering 5 or more participants.
- If you company requires a price quotation.
Event Manager Contact: marilyn.b.turner(at)nyeventslist.com
You can also contact us if you require a visa invitation letter, after ticket purchase. 
We can also provide a certificate of completion for this event if required.

NO REFUNDS ALLOWED ON REGISTRATIONS 
-----------------------------------------------------------------
This Event Listing is Promoted by
New York Media Technologies LLC in association
with METRICSTREAM INC
http://www.NyEventsList.com
http://www.BostonEventsList.com
http://www.SFBayEventsList.com
-----------------------------------------------------------------
MYL170907CEV MYL170915UPR MAR170926UPT

• 08.30 AM - 09.00 AM: Registration
• 09.00 AM: Session Start
• Introduction to Veterinary Antimicrobials and Antivirals
• Introduction
  • Definitions
  • History
  • Ideal Properties
    • Bacteriostatic vs bactericidal
    • Gram + vs Gram –
    • ADME
    • Resistance
  • Basic Concepts of Antimicrobial Therapy
  • Classifying the infection
  • Lipid vs H2O solubility
  • Physiology changes
• Sulfonamides and Diaminopyrimidines
  • Agents
  • MOA
  • Spectrum
  • Resistance Development
  • ADME
  • Adverse Reactions/contraindications/Toxicities
• ß-Lactams: Penicillins
  • Agents
  • MOA
  • Spectrum
  • Resistance Development
  • ADME
  • Adverse Reactions/contraindications/Toxicities
• ß-Lactams: Cephalosporins
  • Agents
  • MOA
  • Spectrum
  • Resistance Development
  • ADME
  • Adverse Reactions/contraindications/Toxicities
• ß-Lactams: Carbapenems
  • Agents
  • MOA
  • Spectrum
  • Resistance Development
  • ADME
  • Adverse Reactions/contraindications/Toxicities

• Aminoglycosides & Aminocyclitols
  • Agents
  • MOA
  • Spectrum
  • Resistance Development
  • ADME
  • Adverse Reactions/contraindications/Toxicities
  • Agents
• Tetracyclines
  • MOA
  • Spectrum
  • Resistance Development
  • ADME
  • Adverse Reactions/contraindications/Toxicities
• Lincosamides
  • Agents
  • MOA
  • Spectrum
  • Resistance Development
  • ADME
  • Adverse Reactions/contraindications/Toxicities
• Macrolides, Azalides & Ketolides
  • Agents
  • MOA
  • Spectrum
  • Resistance Development
  • ADME
  • Adverse Reactions/contraindications/Toxicities
• Fluoroquinolones
  • Agents
  • MOA
  • Spectrum
  • Resistance Development
  • ADME
  • Adverse Reactions/contraindications/Toxicities
• Phenicols
  • Agents
  • MOA
  • Spectrum
  • Resistance Development
  • ADME
  • Adverse Reactions/contraindications/Toxicities
• Miscellaneous
  • Agents
  • MOA
  • Spectrum
  • Resistance Development
  • ADME
  • Adverse Reactions/contraindications/Toxicities
• Dosage regiment design
  • CLSI-VAST
  • AMDUCA
  • Extra-label use